Although several basic questions regarding their biological principles still remain to be answered, many specific characteristics of microRNAs in combination with compelling therapeutic efficacy data and a clear involvement in human disease have triggered the biotechnology community to start exploring the possibilities of viewing microRNAs as therapeutic entities. This review serves to provide some general insight into some of the current microRNAs targets, how one goes from the initial bench discovery to actually developing a therapeutically useful modality, and will briefly summarize the current patent landscape and the companies that have started to explore microRNAs as the next drug target. (Circ Res. 2012;110:496-507.) 
W ith the discovery of microRNAs (miRNAs) being powerful regulators in a wide variety of diseases, it is only a logical consequence that the possibilities of viewing miRNAs as therapeutic entities are being explored. In today's competitive and financially restricted pharmaceutical environment, there are some high demand criteria that must be met before a compound will be considered interesting enough to pursue, that is, worth the financial risk. A successful new drug must fulfill an unmet medical need, should show a clear benefit in safety or efficacy over the current standard of care, and consist of a compound that has attractive pharmacokinetic (PK) properties. Recent animal and even human efficacy data indicate that anti-miR compounds that inhibit specific miRNAs, have the potential to become a whole new class of drugs. MiRNAs have several significant advantages in that they are small and comprise of a known sequence that is often completely conserved among species, which are very attractive features from a drug development standpoint. Based on lessons learned from antisense technologies, very potent oligonucleotide chemistries to target miRNAs, known as anti-miRs, are currently being generated. A bit further behind those efforts are the efforts to design and deliver pharmacologically active synthetic miRNAs, or miR mimics/ mimetics. For the design of anti-miRs, these efforts have given rise to chemistries that produce oligonucleotide drug candidates that bind to their cognate miRNA targets with remarkable affinity and specificity and have suitable druglike qualities such as increased stability and pharmacokinetics. This review serves to provide some insights into the current landscape for targeting miRNAs in disease and the path from translating a bench discovery into a therapeutically useful modality. Although some examples of interesting miRNA targets and companies developing miRNA therapeutics are highlighted, this review is by no means complete, and many more miRNA therapeutics and companies developing them will undoubtedly follow.
Discovery Research
Scientific freedom in an academic setting often allows for making grand, frequently unexpected discoveries. The primary credit for opening up the field of miRNA research goes to the labs of Ambros and Ruvkun. In 1993, these labs made the link between the findings that the lin-4 gene does not encode a protein product but instead gives rise to a small RNA, 1 and the discovery that LIN-14 protein synthesis is inversely regulated by lin-4 RNA. Subsequent sequence analysis showing complementarity of lin-4 to the 3Ј untranslated region of the lin-14 gene revealed the first miRNA-mRNA interaction. 2 Although these initial discoveries were made in Caenorhabditis elegans, the detection of miRNA homologs in many vertebrate species 3 was what really triggered intense research efforts to start unveiling basic concepts of miRNA biogenesis and function. Today, thanks to many profiling and gain-and-loss of function studies, it has become widely appreciated that miRNAs play a major role in many different diseases in both animals and humans. 4 Genetic models of specific miRNAs, in combination with the ease by which miRNAs can be therapeutically manipulated in vivo, have generated compelling efficacy data and motivated the biotechnology community to start exploring some of these miRNAs as drug targets in a diversity of diseases. It is up to academic institutes and investigators to ensure that enticing efficacy data showing a beneficial effect of either genetic or therapeutic regulation in a disease setting is filed on to stake a claim to the intellectual property. Safety is an important determinant in drug development, so the miRNAs that are more tissue restricted will be preferred, especially for the more chronic indications. Additionally, because drug development is guided by the financial gain, another consideration will be the market for the disease indication in which the miRNA therapeutic would be applicable and how the miRNA therapeutic would compare to the current standard of care from an efficacy and financial standpoint.
One way to therapeutically mimic or reexpress a miRNA is by using synthetic RNA duplexes designed to mimic the endogenous functions of the miRNA of interest, with modifications for stability and cellular uptake. The "guide strand" is identical to the miRNA of interest, whereas the "passenger strand" is modified and typically linked to a molecule such as cholesterol for enhanced cellular uptake. However, because the guide strand must function as a miRNA and the cell must recognize it as such, the allowed chemically modifications are limited. Additionally, it should be noted that although this method would replace the miRNA levels lost during disease progression, it will also result in the uptake by tissues that do not normally express the miRNA of interest, resulting in potential off target effects. Delivery to the appropriate cell type or tissue is an important aspect of effective miRNA mimicry to prevent unwanted side-effects. Another way to increase the level of a miRNA is by the use of adenoassociated viruses (AAV). Delivered in viral vectors, the miRNA of interest can be continually expressed, resulting in robust replacement expression of miRNAs downregulated during disease. Additionally, the availability of a number of different AAV serotypes allows for the potential tissuespecificity due to the natural tropism toward different organs of each individual AAV serotype as well as the different cellular receptors with which each AAV serotype interacts. The use of tissue-specific promoters for expression allows for further specificity in addition to the AAV serotype. Furthermore, AAV is currently in use in a number of clinical trials for gene therapy, of which the safety profiles have looked quite well. In line with this, Kota et al 5 recently showed AAV-mediated delivery of miR-26a blunts tumor genesis in a mouse model of liver cancer.
However, by far the most widely used approach to regulate miRNA levels in vivo is by using anti-miRs. Anti-miRs are modified antisense oligonucleotides harboring the full or partial complementary reverse sequence of a mature miRNA that can reduce the endogenous levels of an miRNA. The key requirements for an anti-miR are that the chemistry must be cell permeable, cannot be rapidly excreted, must be stable in vivo, and should bind to the miRNA of interest with high specificity and affinity. 6 -8 Several modifications have been used in vivo thus far. These chemical modifications include 2Ј-O-methyl-group (OMe)-modified oligonucleotides and locked nucleic acid (LNA)-modified oligonucleotides, in which the 2Ј-O-oxygen is bridged to the 4Ј-position through a methylene linker to form a rigid bicycle, locked into a C3Ј-endo (RNA) sugar conformation. 9 Another chemical modification applied to enhance oligonucleotide stability is the balance between phosphodiester and phosphorothioate linkages between the nucleotides, with phosphorothioate providing more stability to the oligonucleotide and making it more resistant to nucleases. The different anti-miR chemistries were previously reviewed in more detail. 10 Because the anti-miR therapeutics are currently more advanced than the miRNA mimics, we will focus on miRNA inhibition for the remainder of this review. A subset of the miRNAs of which inhibition has shown therapeutic promise and that are actively being pursued as clinical candidates are outlined below and schematized in Figure 1 .
MiR-122 in Hepatitis C Virus
A hepatic-specific miRNA, miR-122, was shown to be of critical importance to the replication of hepatitis C virus 11, 12 Sequestration of miR-122 with antisense constructs targeting the miRNA significantly reduced the replication of HCV RNA, suggesting that miR-122 may present a target for antiviral intervention. 12 Only several months after the initial reports on miR-122, Krutzfeldt et al reported on the feasibility of manipulating miRNA levels in vivo, including miR-122 levels, using intravenous administration of a novel class of chemically engineered oligonucleotides, termed "antagomirs." These chemically modified oligonucleotides are complementary to the mature miRNA sequence and are conjugated to cholesterol to facilitate cellular uptake. These initial experiments validated that systemic delivery through intravenous administration efficiently reduced the miRNA of interest for an extended period of time in multiple tissues in vivo. 13, 14 Subsequent studies using systemic delivery of an unconjugated LNA-containing anti-miR potently antagonized miR-122 in mice and nonhuman primates. 15, 16 Nonclinical studies of up to 13 weeks in 2 species support the development of this anti-miR and a recent preliminary report indicates that the safety profile of this LNA-modified oligonucleotide is remarkably similar to other drugs in this class. There were no apparent hepatic morphological changes associated with inhibition of miR-122 in these studies. The inhibition of miR-122 by this LNA-anti-miR was also shown to be safe and efficacious in chronically infected chimpanzees by suppressing HCV viremia and improving HCV-induced liver pathology. 17 Clinical trials using anti-miR-122 against HCV are currently ongoing (see section Initial Clinical Trials).
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MiR-208 in Cardiac Remodeling
One of the first reports on a genetic deletion of a particular miRNA was on miR-208a. MiR-208a is the only cardiacspecific miRNA annotated thus far and is transcribed with its host gene, ␣-myosin heavy chain (␣MHC). 18 Although the expression level of miR-208a remains relatively stable during cardiac stress, this miRNA appears to play a key role in the expression of ␤MHC in response to cardiac stress and fulfills a dominant function in regulating cardiac hypertrophy and remodeling. 18 In response to pressure overload by thoracic aortic constriction or signaling by calcineurin, a calcium/calmodulin-dependent phosphatase that drives pathological remodeling of the heart, miR-208a null mice showed virtually no hypertrophy of cardiomyocytes or fibrosis and were unable to upregulate ␤MHC expression. Because miR-208a expression does not change significantly in response to stress, its requirement for stress-dependent cardiac remodeling suggests that it cooperates with stress signaling to reprogram cardiac gene expression. Efficacy studies using systemic delivery of an LNA-modified anti-miR recently showed that therapeutic silencing of miR-208a through subcutaneous delivery of anti-miR-208a prevents pathological cardiac remodeling, functional deterioration, and lethality during diastolic heart disease. These beneficial effects correspond to significant changes in miRNAs within plasma. 19 The cardiac specificity, the dedication of miR-208a to the cardiac stress response but not to normal cardiac development and the potent therapeutic benefit of anti-miR-208 in rodent models of heart failure make miR-208 (and its downstream effectors) an attractive therapeutic target in the setting of heart disease.
MiR-155 in Inflammatory Disease
An important regulator of the immune system is miR-155. Genetic deletion indicated that miR-155 has an important role regulating T helper cell differentiation, at least in part, by regulating cytokine production. 20 Follow-up studies showed that exposure of cultured macrophages and mice to lipopolysaccharide lead to upregulation of miR-155 and that the transcription factor c/ebp ␤ is a direct target of miR-155. Interestingly, expression profiling of lipopolysaccharidestimulated macrophages combined with overexpression and silencing of miR-155 in murine macrophages and human monocytic cells uncovered marked changes in the expression of granulocyte colony-stimulating factor, a central regulator of granulopoiesis during inflammatory responses. 21 Consistent with these data, silencing of miR-155 in lipopolysaccharide-treated mice by systemically administering a LNAmodified anti-miR resulted in derepression of the c/ebp ␤ isoforms and downregulation of granulocyte colonystimulating factor expression in mouse splenocytes, which indicates the potential of miR-155 antagonists for the treatment of chronic inflammatory diseases. 21
MiR-21 in Fibrosis
MiR-21 is one of the most dynamically regulated miRNAs in various pathological settings, ranging from cancer to heart disease. Several years ago, Thum et al 22 demonstrated that in vivo knockdown of miR-21 with antagomirs blunted cardiomyocyte hypertrophy, inhibited and reversed interstitial fibrosis, and attenuated cardiac dysfunction after thoracic aortic banding. The ability of antagomirs against miR-21 to regulate cardiac disease was attributed to regulation of MAP kinase signaling pathways in cardiac fibroblasts through the miR-21 target, Spry1, a negative regulator of MAP kinase signaling. Although both genetic deletion of miR-21 and anti-miR-based inhibition of miR-21 failed to result in an overt phenotype at baseline and was incapable of blocking cardiac remodeling during stress in one report, 23 others have shown that genetic deletion or anti-miR based inhibition induces therapeutic relevance in inhibiting fibrosis in different tissues 24 -26 and in cancer. 27 Although the contradicting results regarding cardiac remodeling remain unexplained, based on the additional anti-miR findings, inhibition of miR-21 is actively being explored for therapeutic applications in both cancer and fibrotic diseases.
MiR-92a in Neoangiogenesis
In 2009, Dimmeler et al 28 reported on the effects of miR-92a, which is a member of the miR-17/92 cluster, in neoangiogenesis. Inhibition of miR-92a in vivo with intravenous administration of an antagomir resulted in enhanced blood vessel growth as well as functional improvement of damaged tissue in models of hind limb ischemia and myocardial infarction. 28 The neoangiogenic effect of inhibiting miR-92a in vivo was attributed to the derepression of the multiple proangiogenic factors, including integrin ␣5, a direct target of miR-92a. The proangiogenic capacity of miR-92a inhibition is currently being explored as a potential therapy in diseases like ischemic heart disease or peripheral artery disease.
MiR-33 in Metabolic Disease
An miRNA that has gained a lot of attention in the last few years is miR-33. MiR-33a and miR-33b are both embedded within introns of the sterol regulatory element-binding proteins (SREBPs). SREBP2 coexpresses miR-33a, whereas miR-33b is coexpressed with SREBP1. 29 These host genes encode key transcriptional regulators of genes involved in cholesterol biosynthesis and uptake, and, as often the case with intronic miRNAs, miR-33a/b are involved in coregulating this process. In 2010, several groups showed that miR-33a/b targets the adenosine triphosphate-binding cassette transporter A1 (ABCA1), an important regulator of highdensity lipoprotein (HDL) synthesis and reverse cholesterol transport. Inhibition of miR-33 in mice using either LNAmodified anti-miRs 29, 30 or lentiviral overexpression of anti-miR-33 31 caused an upregulation of ABCA1 expression and increased cholesterol efflux, and injecting mice fed a Western-type diet with LNA-modified antisense oligonucleotides resulted in elevated circulating HDL levels. 29 These data strongly suggest that inhibition of miR-33 may be atheroprotective. More recently, it was reported by Rayner et al 32 that extended inhibition of miR-33 using an 2Ј fluoro/ methoxyethyl-modified (2ЈF/MOE-modified) phosphorothioate backbone antisense oligonucleotide against miR-33 in mice deficient for the LDL receptor with established atherosclerotic plaques, increased circulating HDL levels, and enhanced reverse cholesterol transport to the plasma, liver, and feces. Consistent with this effect, the anti-miR-treated mice showed reductions in plaque size and lipid content, increased markers of plaque stability, and decreased inflammatory gene expression. 32 Inhibition of miR-33a/b in nonhuman primates raises plasma HDL and lowers VLDL triglycerides indicating therapeutic promise for the treatment of dyslipidemias that increase cardiovascular disease risk. 33 Together, these studies indicate that raising HDL levels by anti-miR-mediated inhibition of miR-33 through its effects on cholesterol transport and atherosclerosis regression may be a promising therapeutic approach to treat vascular disease.
MiR-451 in Myeloproliferative Diseases
MiR-451 is part of a bicistronic cluster (miR-144/451) that is highly expressed during erythrocyte development. Although normally erythrocyte formation occurs throughout life in response to cytokine signaling, last year the groups of Olson, Weiss and O'Carroll showed that mice lacking miR-451 34 or lacking the miR-144/451 cluster 35, 36 display a reduction in hematocrit, an erythroid differentiation defect, and showed an ineffective erythropoiesis in response to oxidative stress.
MiR-451 appears to be an especially intriguing miRNA in that it has very few predicted targets. Among these targets, 14-3-3zeta, an intracellular regulator of cytokine signaling, is repressed by miR-451 and is upregulated in miR-451-deficient erythroblasts. Conversely, inhibition of 14-3-3zeta, using shRNA, rescues the erythrocyte differentiation defect 34 and protects miR-144/451-deficient erythrocytes against peroxide-induced destruction while restoring catalase activity. 36 These findings reveal an essential role of 14-3-3zeta as a mediator of the proerythroid differentiation actions of miR-451 and highlight the therapeutic potential of miR-451 inhibitors. Although the original manuscript from Patrick et al 34 showed that antagomir-based inhibition of miR-451 was able to phenocopy the erythroid differentiation defect seen in the miR-451 mutant animals, it will be of great interest to examine how oligonucleotide-based inhibition of miR-451 will affect the progression of some myeloid proliferative diseases characterized by an increase in hematocrit, such as polycythemia vera.
MiR-15 Family in Cardiac Regeneration and Injury
The miR-15 family consists of multiple miRNAs (miR-15a, miR-15b, miR-16 -1, miR-16 -2, miR-195, and miR-497) and is consistently found to be upregulated in different settings of disease, including cancer and cardiac diseases. Although the exact functions of this miRNA family are still being explored in vivo, these miRNAs are predicted to influence cell survival and cell cycle regulation. For cardiac indications, this role would imply that miR-15 could serve as a therapeutic target for the manipulation of cardiac remodeling and function in the settings of ischemic heart disease, where the limited regenerative capacity of the heart is unable to restore the damaged tissue. In line with this hypothesis, a recent study by Porrello et al 37 revealed that several members of the miR-15 family were upregulated during postnatal development of the heart. Because mammalian cardiomyocytes withdraw from the cell cycle during early postnatal development, these miRNAs might be involved in mechanisms that govern the reduced ability of cardiomyocytes to proliferate after birth. Using global gene profiling and argonaute-2 immunoprecipitation approaches, it was shown that miR-195 regulates the expression of a number of cell cycle genes, including checkpoint kinase 1 (Chek1) and that knockdown of the miR-15 family in neonatal mice with LNA-modified anti-miRs was associated with an increased number of mitotic cardiomyo-van Rooij et al Developing MicroRNA Therapeutics cytes and derepression of Chek1. 37 Even more recent it was shown that miR-15 family inhibition, in the setting of ischemic injury, reduces infarct size and improves cardiac function. 38 It will be interesting to explore the effects of miR-15 inhibition in heart disease, in which loss of viable tissue or lack of regeneration is causally related to the disease.
MiR-103/107 in Metabolism
MiR-103 and miR-107 are related miRNAs that differ by only 1 base in their 3Ј region. Although they are intronically located within the pantothenate kinase (PANK) genes, at least in mice, their expression does not correlate with expression of the host genes. 39 Bioinformatic target prediction programs indicate that these miRNAs can potentially regulate mRNA genes in pathways that involve cellular Acetyl-CoA and lipid levels. 40 Recently, Stoffel et al 41 showed that the expression of miR-103 and miR-107 is upregulated in obese mice and that antagomir-based silencing of miR-103/107 leads to improved glucose homeostasis and insulin sensitivity, whereas gain of miR-103/107 function in either liver or fat is sufficient to induce impaired glucose homeostasis. Target identification analysis indicated caveolin-1, a critical regulator of the insulin receptor, to be a direct target of miR-103/ 107. The upregulation of caveolin-1 on miR-103/107 inhibition in adipocytes correlates with stabilization of the insulin receptor, enhanced insulin signaling, decreased adipocyte size, and enhanced insulin-stimulated glucose uptake. These findings demonstrate the potential importance of miR-103/ 107 to insulin sensitivity and identify these miRNAs as potential new targets for the treatment of type 2 diabetes and obesity.
Preclinical Drug Development for Anti-MiRs
With respect to drug discovery, the miRNA revolution of recent years has provided the industry with multiple new opportunities for the identification of new drug targets. These revelations, coupled with recent advances in anti-miR chemistries, suggest that the regulation of miRNAs may be the next innovation in pharmaceutical research. These advances are based on basic research on the role of miRNAs in disease states or in cellular regulation in disease, and, more importantly and more recently, on demonstrations of pharmacological interventions. Based on in vivo efficacy studies showing therapeutic benefit of miRNA regulation (as described in the previous section), potential miR-inhibiting sequences and chemistries can be characterized to further evaluate these entities as suitable drug candidates for preclinical toxicity and pharmacokinetics studies prior to the onset of clinical trials ( Figure 2 ).
Establishing Lead Compound
The discovery and development of a novel therapeutic agent has become more challenging and riskier than ever before because of the high cost of drug development and the more stringent regulatory requirements for drug registration. This new environment has placed a premium on quickly identifying and validating drug candidates, selecting the most effective ones that have good pharmacological activity, and have the best predicted safety and pharmacokinetic profiles. Al-though the initial efficacy testing of miRNA inhibition in an academic laboratory is often done with a validated research tool, regulatory requirements ultimately force the later stages of candidate selection and safety profiling into the industrial arena. Usually, to establish a lead drug compound for traditional low-molecular-weight drugs, many thousands of molecules will be synthesized and screened to generate a single drug candidate. However, screening approaches for lead anti-miR designs can be more focused for the following reasons: the short sequence of the miRNA target and the discrepancy between in vitro and in vivo performance of the anti-miRs forcing researchers to screen for efficacy in vivo.
The primary reason for anti-miR screens often being limited is that miRNA sequences are short, and there are limited numbers of sequences that will bind and sequester any single miRNA. Although the number of testable molecular species (permutations) will increase when chemical modifications are introduced into the sequence, the nature, location, and the number of these modifications is restricted for To advance a miRNA target toward the clinic, there is a defined process that is generally followed before the onset of clinical trials, which involves optimization of suitable drug candidates and performing pharmacokinetics (PK), pharmacodynamics (PD), and absorption, distribution, metabolism, and excretion (ADME) studies to obtain all required insights into the anti-miR drug. Preclinical toxicity testing is performed to assess whether a drug is safe enough to move into humans. To move an anti-miR drug into clinical trials, all the nonclinical data on the characterization of the drug substance and the safety in animals are compiled along with a clinical protocol for an initial usually short exposure of humans to ascending doses of the new therapeutic (Phase I clinical trial). These preclinical data required for an Investigational New Drug (IND) or Clinical Trials Application will allow regulators authorities and ethics committees to assess whether the drug product has been well enough characterized to establish whether it should be safe in the initial clinical protocol and that the clinical protocol design and investigators will monitor the subject's safety.
anti-miR chemistries. This limited number of possible permutations allows for a focused screening effort compared with more classic drugs. It is possible to vary the location of modifications, and the length of the putative binding species, but the range of acceptable chemical modifications have been well defined by the existing antisense literature and the "universe" of modifications is well understood.
One of our recent observations is that although it is possible to select optimal sequence for binding and sequestration in vitro, to fully optimize the distribution and uptake by target tissues it is preferable to select anti-miR chemistries on the basis of in vivo performance in relevant animal models because they allow the researcher to assess the true pharmacological profile and therapeutic window for a given sequence and its modifications. At times it may even be useful or more optimal to screen in disease models in which it is possible to assess the performance of the putative drug candidate with the appropriates stresses and in the appropriate host environment when miRNA perturbations best approximate the human condition. As such, miRNA regulation under baseline conditions might not always result in a measurable downstream effect. The use of animal models, including animal models of disease, offer an overall assessment of the pharmacokinetic (PK, the inhibitory effect of the anti-miR on the miRNA), pharmacodynamic (PD, the effect of the anti-miR on target derepression of direct mRNA targets of a specific miRNA) and toxicity profiles before committing to a traditional nonclinical development program and its attendant GLP toxicity and pharmacokinetics studies. These studies represent a significant investment in time, resources, and animals and should be initiated only when there is ample evidence of good activity, distribution, and safety in pharmacology screens.
Pharmacokinetics, Pharmacodynamics, and Absorption, Distribution, Metabolism, and Excretion
In search for lead sequences and anti-miR chemistries, the pharmacokinetic properties of the compounds become critically important in guiding the selection of a drug candidate for development. The pharmacokinetic behavior of a compound in animals serves as a basis for predicting how a compound will behave in humans and represents an integral component of the decision making process whereby new chemical entities are selected for development.
Most anti-miRs use modifications of the typical nucleic acid ribose sugar backbone with 2Ј-modifications, which distribute broadly but tend to accumulate in a characteristic pattern with most in liver, kidney and phagocytically active cell types. The field is learning that each chemical modification or length change in a candidate sequence introduces variations from the typical pattern. Thus it becomes important to characterize each candidate sequence (and its specific modifications) in an animal model predictive for humans. This information is normally obtained at an early stage of preclinical evaluation.
For a modified phosphorothioate oligonucleotide to target a miRNA, there are distinctive attributes of its pharmacokinetics and pharmacology that differentiate it from typical (low molecular weight) drugs. The most obvious one is that plasma levels of an anti-miR or miR-mimetic are cleared from plasma within hours by uptake into tissues, 42, 43 but, once inside cells, many of the modified oligonucleotide used as anti-miRs are so metabolically stable that their clearance is slow, and half-lives in tissues are often in on the order of weeks, providing therapeutic benefit long after blood levels are near zero. Because pharmacological activity is the result of the anti-miR being pharmacologically active in tissue cells not plasma, the initial high levels of anti-miR detection in the plasma are of limited value in predicting the extent and duration of the pharmacological effect of the anti-miR. The key factor that controls (and predicts) the pharmacological effects and their duration (pharmacodynamics) are target tissue concentrations not the initial plasma concentrations. In clinical trials, it is not feasible to get tissue samples to measure drug levels, and, for that reason, surrogates for target tissue must be established. Various surrogates have been considered including peripheral blood monocytes, subcutaneous fat biopsies, and equilibrium plasma concentrations. Equilibrium plasma concentrations occur after the plasma has been cleared of drug and represent drug that has equilibrated from the depots in the tissue into the plasma.
The time course and nature of the pharmacological effects (or pharmacodynamics) of anti-miRs are often complicated by the fact that the pharmacology is the summation of the derepression of families of genes and the downstream events produced by derepression of multiple target genes controlled by that particular miRNA. Thus, for the downstream effects of some anti-miRs, there can be a delay in their onset and in their offset. This delay has been reported for the miR-122 inhibitor and its effects on cholesterol. 9 Similar phenomena are being observed with other anti-miRs, such as against miR-208 and a delayed effect on downregulating ␤-MHC. 44 Delays in observing pharmacodynamics effects are atypical for most low-molecular-weight drugs and are more akin to so-called disease-modifying agents, in which it is established that pharmacological activity is related to the sum of pharmacological effects over time that cause a change in the disease phenotype.
The poly-anionic molecules that are currently employed as anti-miRs are highly water-soluble, with molecular weights of 2-6 kD, and are not good candidates for oral administration with intestinal absorption without the aid of permeation enhancers. 45 Even with permeation enhancers, intestinal absorption of anti-miRs is going to be limited by size and charge. Thus it remains a formulation challenge to create novel delivery techniques for oral administration. At present, administration of oligonucleotide anti-miR is dependent on parenteral administration, and the 2 routes currently being used are intravenous and subcutaneous injections or infusions. Because of their high water solubility, it is possible to dissolve anti-miRs in aqueous solutions at volumes that are amenable to self-administration by the subcutaneous route, and, with their long biological half-lives, it may be possible that anti-miRs can be administered relatively infrequently, thus reducing frequency of injection.
van Rooij et al Developing MicroRNA Therapeutics Toxicity Testing
A major contributor to the high attrition rate in drug development continues to be unanticipated toxicity. The goal of preclinical toxicity evaluations is to screen out drugs with unanticipated effects and to determine the target organs for toxicities and characterize the nature of the toxicities. To this end, toxicity studies with anti-miRs face interesting challenges. In contrast to many other therapeutic modalities, anti-miR drugs are designed knowing that they will affect families of genes under the control of the target miRNA. This differs from most other drugs that are generally designed to affect 1 target but may inadvertently affect more than 1.
Although miRNAs often target many related genes involved in the pathway or cellular process that is intended to be manipulated by the anti-miR therapeutic, the same miRNA probably will also target unrelated genes and possibly produce undesired changes in gene expression. Another challenge for toxicologists and pharmacologists is that although miRNAs tend to be highly conserved across species, 46 there may be less conservation in the families of genes that the same miRNA targets in different species; or, there may be a difference in miRNA subfamilies across species, with each species being dependent on a slightly different combination of miRNA subtypes, and each miRNA subtype may have its own distinctive fingerprint of mRNAs that it represses. Thus for each new anti-miR sequence that goes into clinical trials there may be differences in the responses between the animal models and man. Clearly, the goal of toxicology studies is to characterize the biological response to therapy in animals as closely related to man as possible, and thus there is the precedent for using nonhuman primates to characterize toxicity. This approach is accepted but its limitations, particularly in the field of miRNA therapeutics, must be acknowledged as each anti-miR drug moves into clinical trials for the first time.
In principle, the assessment of toxicity of a miRNAtargeting (or mimicking) therapeutic is very similar to the characterization of toxicity for a typical small molecule. A typical toxicology program to move a drug into clinical trials is provides information on the genetic toxicology of the candidate drug, effects on critical organ systems, and the characterization of effects in 2 species after repeated administration of the candidate drug in a rodent and nonrodent species. Although procedurally there are few differences between the toxicity testing programs between small molecules and oligonucleotide drugs, there are some key differences as well.
The main differences in the toxicity studies between a small molecule and an anti-miR are related to how toxicities might arise rather than the process by which toxicity is characterized. The sources of toxicity after administration of a miRNA targeting agent can be classified broadly as toxicities related to the chemistry or class (hybridization independent toxicities) and toxicities arising from hybridization events. Chemistry-related effects are common sources of toxicity for oligonucleotide therapeutics. One example of this type of effect could arise from anti-miR, binding to a protein and modulating protein function. Phosphorothioate oligonucleotides can inhibit the tenase complex in the intrinsic clotting cascade, 47 activate the alternative pathway of the complement cascade, 48 and activate innate immunity. It is the activation of innate immunity that has proven to be the most complex and difficult to avoid. In brief, DNA and RNA are recognized by innate immune receptors much the same way as viruses, thereby setting off cascades of events. Chemical modifications of oligonucleotides, particularly those at the 2Ј position of the ribose sugar, reduce the proinflammatory effects of oligonucleotides, but such effects have not yet been totally eliminated.
Hybridization-dependent effects can range from toxicities that result from excess pharmacological that might occur after binding to the intended target (exaggerated pharmacology) to toxicities that result from binding and inactivation of an unintended target RNA (off-target effect). It is possible to use Watson and Crick base-pairing rules to attempt to predict potential sites for off-targets hybridization-dependent effects and to use microarrays or other tools for measure RNA levels to characterize off-target effects. Examples of hybridizationdependent toxicities would be toxicities that might arise if the sequence of the anti-miR had a near perfect match in the genome. It could then be envisioned that the anti-miR could bind to that related sequence and produce an antisense effect on that unintended target and produce toxicity. This type of off-target effect can be avoided by diligent screening of potential anti-miR sequences. However, even if there is a near-perfect match in the genome, an off-target effect like that mentioned is unlikely for a multitude of reasons, including the fact that the design of anti-miR chemistries do not generally support antisense-cleavage of a target. 49 -51 In addition, if there are any highly homologous targets they would have to be in tissues where the antagonist was concentrated at sufficient concentrations to produce activity and would have to be an mRNA target that when its expression was reduced produced some toxicity. All of these criteria would have to be met for an anti-miR to produce an off-target hybridizationdependent toxicity.
An interesting concept to consider in toxicity testing for an anti-miR chemistry is the concept of saturation of pharmacology and its implications for dose and dose regimen. For an anti-miR, there is a limited number of available miRNAs to bind and sequester, so it should be possible to sequester all of the target miRNAs in a cell at some finite concentration. Thus, adding more anti-miR will not produce greater sequestration and therefore no additional pharmacology. Establishing the doses and tissue concentrations that reach this level of total sequestration is probably a key function of nonclinical toxicity and pharmacokinetic studies and has important implications for the design of dose regimens for clinical trials. Understanding the concentration of an anti-miR and the rate of clearance of the anti-miR chemistry would allow one to design dose-sparing regimens in which, once drug concentrations achieve total miRNA sequestration, then the only additional anti-miR needed would be that required to replace the anti-miR cleared or the anti-miR required to sequester newly synthesized miRNAs. Thus, it should be possible to use information on the half-life of the anti-miR drug and the turnover rate of the miRNA targets to estimate dosing needs. Any drug given in excess of the amount required to fully sequester the available miRNA target is simply drug that is available to produce non-target-related effects.
The optimization of chemistry, sequence, and length of an oligonucleotide as well as the dose regimen are all essential to selecting a successful miR-antagonist and designing the appropriate clinical trials. Adhering to the wisdom of Paracelsus (1493-1541) "Dosis facit venenu" (dose makes the poison) nonclinical studies should establish safe levels and characterize unwanted effects. With the tools that are available to screen for toxicity and an understanding of the kinetics of the drug and the miRNA drug target, it should be possible to move safe compounds into clinical trials and to design safe clinical trials that minimize ineffective and potentially toxic over exposures.
Initial Clinical Trials
To date, there is one anti-miR chemistry in clinical trials, which is miravirsen (an inhibitor of miR-122; see above). To advance an anti-miR drug from the bench into clinical trials, there is a well-defined process whereby nonclinical data on characterization of the drug substance and the safety in animals and are compiled along with a clinical protocol for an initial usually short exposure of humans to ascending doses of the new therapeutic. The data required for an Investigational New Drug (IND) or Clinical Trials Application allow regulatory authorities and ethics committees to assess whether the drug product has been characterized sufficiently to establish whether it should be safe in the initial clinical protocol and that the clinical protocol design and investigators will monitor the subject's safety. As the drug proceeds through clinical trials, the level of animal toxicity testing and level of understanding of the manufacturing process and its controls increase in intensity to support the longer-term use of the new therapeutic in clinical trials initially in healthy subjects and later in patients with the relevant diseases. Just recently, data from the Phase 2a trial were released indicating that miravirsen, the first miRNA-targeted drug to enter clinical trials, provided continuous and prolonged antiviral activity well beyond the end of active therapy in patients and was well tolerated in patients infected with HCV (http://www.santaris.com/news/2011/10/03/santaris-pharmareport-new-clinical-data-miravirsen-phase-2a-study-treathepatitis-c). Even as a single agent, there were some patients whose viremia was reduced below the level of detection after 4 weeks of dosing with 7 mg/kg per week. The data demonstrate clinical utility for an miR-targeting therapeutic in human disease. Miravirsen is serving as a model compound for future anti-miR therapeutics, and many more miRNA therapeutics are expected to enter clinical trials as new disease targets are identified and new sequences show activity in diseases. There is great anticipation for the arrival of drugs that can reprogram disease cells into healthy cells and tackle diseases from a total novel set of targets.
Current Status of MiRNA Therapeutics
Based on reasons mentioned above, there is great excitement surrounding miRNAs as therapeutic entities. From a scientific point of view, multiple miRNAs appear to be attractive therapeutic targets and chemistries exist that can inhibit miRNAs in a safe manner. Perhaps, not surprisingly, the explosion of scientific research on miRNA biology has engendered a considerable amount of innovation in this area as reflected by the significant increase in the number of patent application filings over the last 10 years. To provide a snapshot of the current commercial uses and development of miRNA-based therapeutics and diagnostics, we briefly summarize the miRNA patent landscape in the United States and Europe and describe several of the biotechnology companies that are presently developing miRNA-based products and services.
MicroRNA Patents in the United States and Europe
Observing the trends in miRNA patent activity lends insight not only into the scientific progress in the field but also foreshadows aspects of the field that are likely to be ripe for commercial development. To obtain an overall picture of the miRNA patent landscape in the United States and Europe, one can conduct a search in the patent database for all published applications and patents related to miRNAs and their use. In doing so, our search resulted in a total of 2136 published patent documents, 1661 of which were US publications and 475 of which were European publications. A breakdown of the number of application filings and patents issued by year from 2000 -2010 reveals a dramatic increase in miRNA-related application filings beginning in 2002 in the United States and peaking in 2008, with more than 300 filings (Figure 3) , which reflects the intense research and development occurring in this nascent field. The number of European applications filed continues to increase since the first filings in 2003. The difference in trends between the number of US and European miRNA-related filings is due, at least in part, to the filing strategy that is commonly used to pursue patent protection in Europe. Generally, patent applicants initially file an international application under the Patent Cooperation Treaty, which delays national stage filings in other countries, like Europe, for an additional 18 months. After a lag of 4 years from the first application filings, the first US patent was To determine the particular technical areas in which the patent filings were concentrated, we separated the patent documents in the US data set by their International Patent Classification (IPC) codes. The IPC system categorizes patent documents according to the technical field that characterizes the described invention ( Figure 4A ). Although the miRNA-related patent documents spanned over 60 IPC code categories, almost 50% of the US patent documents were classified as relating to some type of medicinal preparation, relating to both pharmaceutical compositions comprising miRNA-modulating compounds, as well as methods of modulating miRNA activity for the treatment of diseases. Another smaller but notable grouping of documents were those related to assays and apparatus for detecting or measuring miRNAs. This group of patent documents accounted for 22% of all the filings and included applications related to creation of miRNA expression profiles and methods for detection and/or quantification of miRNA in various samples.
The remainder of the US patent documents was spread across various categories, including plant-related miRNAs, genetic engineering and tissue or cell cultivation, nucleic acids and their derivatives, and libraries and methods of preparing or screening libraries.
An interesting pattern emerged when the patent documents classified as medicinal preparations in Figure 4A were further sorted into specific indications ( Figure 4B ). Patent documents relating to miRNA delivery vehicles or methods accounted for 14% of the filings, whereas applications and patents related to gene regulation constituted 12% of the filings. This latter category included miRNA molecules themselves, compounds targeting miRNAs, and methods of regulating RNA interference. Patent filings directed to multiple therapeutic uses of specific miRNA molecules comprised the majority of the general treatment methods group, which accounted for 11% of the patent documents categorized as medicinal preparations. Applications and patents disclosing diagnostic uses for miRNAs also represented a significant number of the medicinal preparation filings.
With respect to specific disorders, there were a greater number of filings related to methods of treating cancer than any other particular family of diseases or disorders. After cancer, the most prevalent filings were related to the treatment of viral infections (6%), particularly hepatitis C, ocular disorders (5%), inflammatory disorders (5%), cardiovascular disorders (4%), and neurological disorders (4%). Interestingly, many of the indications for which a significant number of patent filings were observed are also considered to be among the top health risks for Americans, such as heart disease, Alzheimer disease, and cancer. The relatively high number of filings related to the treatment of ocular disorders is somewhat surprising. Perhaps the high incidence of these filings reflects the fewer obstacles in delivering nucleic acid therapeutics to the eye.
Companies Developing MiRNA Technologies
Industry support for RNA-targeting therapeutics has been cyclic, with periods of intense excitement followed by periods of apathy, with antisense and siRNA being prime examples of cyclic interest. Some of the luster on siRNA has faded, and there has been a retrenchment and in a few cases abandonment of RNA-targeting therapeutics, but many large companies maintain trimmed-down efforts in RNA-targeting therapeutics, and smaller companies continue to push forward with important proof of concept studies. With the advent of miRNAs as viable therapeutic targets for many serious health conditions, many new companies have been established to translate the exciting scientific discoveries into real-world, commercial uses. At the same time, some older companies, which had an initial focus on the development of siRNAbased compounds, have additionally begun to explore their proprietary chemistries and delivery systems for the design of miRNA inhibitors and mimics. The Table summarizes several companies that are currently developing miRNA-based therapeutic and diagnostic applications.
Founded in 1983, Marina Biotech, based in Bothell, Washington, recently announced the success of oligonucleotides modified with the company's conformationally con- strained nucleotide technology for suppressing miRNA expression in vivo. Similarly, RXi Pharmaceuticals, which was founded in 2003 by Nobel Laureate Craig Mello, is developing "self-delivering RNAi" compounds that contain a combination of nuclease-stabilizing, backbone, and lipophilic chemical modifications. Santaris Pharma, the Denmarkoriginated company that developed the LNA chemistry platform to create oligonucleotide therapeutics with enhanced affinity for their RNA targets, exploited the LNA technology to produce potent oligonucleotide inhibitors of endogenous miRNAs. One such inhibitor is miravirsen, which is currently in Phase II clinical trials for the treatment of hepatitis C as discussed above.
Newer companies have focused their efforts on bringing to market specific miRNA therapeutics for particular indications rather than developing broader-based nucleic acid therapies. Three such companies (miRagen Therapeutics, Regulus Therapeutics, and Mirna Therapeutics), all of which were founded in 2007, have identified various miRNAs that play a role in different disease states and are advancing drug candidates that regulate these miRNAs. In June of 2010, miRagen Therapeutics partnered with Santaris Pharma to design and commercialize miRNA-targeted oligonucleotides utilizing Santaris Pharma's LNA technology for the treatment of cardiovascular disorders. Recently, miRagen Therapeutics announced a partnership with Les Laboratoires Servier, a European pharmaceutical company, to develop 3 miRNAbased therapeutics for the treatment of cardiovascular disorders. Regulus Therapeutics, a joint venture of Alnylam Pharmaceuticals and Isis Pharmaceuticals based in La Jolla, California, is also developing several miRNA therapeutics including oligonucleotide inhibitors of miR-21 for the treatment of fibrotic diseases and cancers, anti-miR-122 for the treatment of hepatitis C, anti-miR-155 for the treatment of inflammatory diseases, and anti-miR-33 for the treatment of metabolic disorders. In 2008, Regulus Therapeutics formed a strategic, worldwide alliance with GlaxoSmithKline to develop miRNA-targeted therapeutics for inflammatory disorders, such as rheumatoid arthritis and inflammatory bowel disease. In 2010, Regulus and GlaxoSmithKline expanded their relationship by entering into a collaboration to develop and commercialize miR-122-targeting drugs for the treatment of various diseases, including hepatitis C viral infection. In addition, Regulus has partnered with Sanofi-Aventis to research and develop miRNA therapeutics for fibrosis. The focus of Mirna Therapeutics, a company formed to accelerate the drug discovery efforts of RNA-based diagnostic company, Asuragen, Inc, is "miRNA replacement therapy" for the treatment of solid cancers. The company has identified tumor suppressor miRNAs, such as miR-34 and let-7, which are downregulated in various types of cancers. The goal of the miRNA replacement therapy strategy is to restore the function of these miRNAs through the use of oligonucleotide mimics. Mirna Therapeutics anticipates the filing of its first investigational new drug application on its tumor suppressor mimics in late 2012 (Table) .
MiRNA-based diagnostics also feature prominently in the commercialization of miRNA-related technologies. In fact, Israel-based Rosetta Genomics was one of the first companies to emerge on the scene in 2000 that capitalized on miRNA discoveries. Rosetta Genomics currently offers four diagnostic tests for characterizing primary tumors from various types of cancer, including lung cancer and mesothelioma, by measuring miRNA expression. Additional tests are in development for renal cell carcinoma and bladder cancer. Asuragen, Inc, founded in 2006, was formed from part of Ambion's molecular biology and diagnostics divisions. Its current focus is miRNA-based diagnostics for cancer (eg, leukemia) and genetic disorders (eg, Fragile X syndrome). It is likely that additional miRNA-based diagnostic companies will become more prevalent in the years to come. Diagnostic tests often have fewer hurdles to obtain regulatory approval as compared with new drugs, and the relatively recent discovery that miRNAs are detectable in the blood provides the basis for minimally invasive methods for detecting and monitoring disease conditions and efficacy of therapeutic regimens (Table) .
Concluding Remarks
There are several significant advantages to miRNAs for becoming a new class of drug targets. Their small size and known and conserved sequence make them attractive candidates from a development standpoint. Additionally, many genetic or oligonucleotide-based gain-and-loss-of function studies have shown very pronounced phenotypes in rodents and even large animal models, whereas miRNA manipulation under baseline conditions oftentimes does not exert overt effects. Furthermore, the direct downstream targets of a single miRNA are commonly related genes that function in a comparable cellular process or signaling cascade. This implies that targeting of a single miRNA probably will result in a dramatic effect due to the combinatorial effect of gene expression changes in all these related downstream targets. The impact of targeting a miRNA sequence is further strengthened by the fact that the genome often contains multiple copies of the same or closely related miRNA sequences, such that targeting of the miRNA sequence will become even more influential. Lessons learned from antisense technologies leapfrogged us into very potent oligonucleotide chemistries that can be applied to target miRNAs, known as anti-miRs, with remarkable affinity and specificity and have suitable drug-like qualities such as stability and pharmacokinetics.
Although there are many reasons to be excited about miRNAs as a new class of drug targets, some aspects of miRNA and anti-miR biology are still relatively unknown and should be taken into account when moving forward. Although a miRNA might target related genes, the fact that a single miRNA can target many genes and the genes that are targeted are cell type-dependent gives a whole new meaning to "off-target effects" compared with a classic drug. Additionally, there are a lot of unknowns surrounding the mode of action of the different anti-miRs. Current data suggest that specific chemistries might affect cellular uptake and differ in degree of blocking the function of a miRNA. Their long-term effect (up to weeks or even months) indicates their stability, but also suggests the cell has a reservoir of anti-miR, which during the course of time, is slowly released into the cytoplasm to bind to or scavenge the newly formed copies of a miRNA. However, the precise mechanism is still unclear, and more in-depth biochemistry will be required to gain more insight.
Despite the unknowns, the interest surrounding miRNAs as novel therapeutic entities is tremendous and the anticipated success of these early forerunners probably will spur the search for additional miRNA therapeutic targets, innovation in the areas of miRNA inhibitors and mimics, and will advance the search for techniques for efficient in vivo delivery of these miRNA therapeutics. We hope that while we are eagerly awaiting more efficacy data in human subjects, the next few years promise to provide many more insights into miRNA and anti-miR biology and will even further strengthen the enthusiasm for this new class of drugs.
